Specific Role of Combination Aclidinium: Formoterol in the Treatment of Chronic Obstructive Pulmonary Disease

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2016 Jan 22

PMID 26792987

Authors

Maria Gabriella Matera

Alessandro Sanduzzi

Mario Cazzola

Affiliations

Soon will be listed here.

Abstract

Co-administration of a long-acting β2-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β2-agonist fixed-dose combination that has been studied for this therapeutic indication.

References

Cazzola M, Matera M, Santangelo G, Vinciguerra A, Rossi F, DAmato G . Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 1995; 89(5):357-62. DOI: 10.1016/0954-6111(95)90008-x. View

Lal C, Strange C . Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015; 16(3):427-34. DOI: 10.1517/14656566.2015.1000861. View

Kessler R, Partridge M, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D . Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2010; 37(2):264-72. DOI: 10.1183/09031936.00051110. View

Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G . Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2(6):472-86. DOI: 10.1016/S2213-2600(14)70065-7. View

Cazzola M, Centanni S, Regorda C, Di Marco F, Di Perna F, Carlucci P . Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther. 2001; 14(1):41-5. DOI: 10.1006/pupt.2000.0267. View

Cazzola M, Molimard M . The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010; 23(4):257-67. DOI: 10.1016/j.pupt.2010.03.003. View

Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera M . The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2003; 17(1):35-9. DOI: 10.1016/j.pupt.2003.09.001. View

Partridge M, Karlsson N, Small I . Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009; 25(8):2043-8. DOI: 10.1185/03007990903103006. View

Mocarski M, Zaiser E, Trundell D, Make B, Hareendran A . Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis. 2015; 10:475-87. PMC: 4358643. DOI: 10.2147/COPD.S75776. View

10.

Calzetta L, Matera M, Cazzola M . Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015; 761:168-73. DOI: 10.1016/j.ejphar.2015.05.020. View

11.

Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, Di Marco F . The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004; 98(12):1214-21. DOI: 10.1016/j.rmed.2004.05.003. View

12.

Mahler D, DUrzo A, Bateman E, Ozkan S, White T, Peckitt C . Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012; 67(9):781-8. DOI: 10.1136/thoraxjnl-2011-201140. View

13.

Moitra S, Bhome A, Brashier B . Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Des Devel Ther. 2015; 9:1989-99. PMC: 4396584. DOI: 10.2147/DDDT.S53150. View

14.

DUrzo A, Rennard S, Kerwin E, Mergel V, Leselbaum A, Caracta C . Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2015; 15:123. PMC: 4213545. DOI: 10.1186/s12931-014-0123-0. View

15.

Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H . Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010; 10:1. PMC: 2822814. DOI: 10.1186/1471-2466-10-1. View

16.

Cazzola M, Calzetta L, Page C, Rogliani P, Facciolo F, Gavalda A . Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol. 2014; 745:135-43. DOI: 10.1016/j.ejphar.2014.10.025. View

17.

Singh D, Jones P, Bateman E, Korn S, Serra C, Molins E . Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014; 14:178. PMC: 4273456. DOI: 10.1186/1471-2466-14-178. View

18.

Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera M . Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015; 761:383-90. DOI: 10.1016/j.ejphar.2015.04.042. View

19.

Hareendran A, Make B, Zaiser E, Garcia Gil E . Evaluation of the psychometric properties of the Early Morning Symptoms of COPD Instrument (EMSCI). Int J Chron Obstruct Pulmon Dis. 2018; 13:1633-1645. PMC: 5965389. DOI: 10.2147/COPD.S152087. View

20.

Cazzola M, Noschese P, Salzillo A, De Giglio C, DAmato G, Matera M . Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. 2005; 99(5):524-8. DOI: 10.1016/j.rmed.2004.10.004. View